Cargando…

Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase?

BACKGROUND: The ACTION trial was initiated to provide evidence from a randomised trial on the effects of chemotherapy in women aged over 70 years where evidence for risk and benefit are lacking. METHODS: This was a randomised, phase III clinical trial for high risk, oestrogen receptor (ER) negative/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leonard, R, Ballinger, R, Cameron, D, Ellis, P, Fallowfield, L, Gosney, M, Johnson, L, Kilburn, L S, Makris, A, Mansi, J, Reed, M, Ring, A, Robinson, A, Simmonds, P, Thomas, G, Bliss, J M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241551/ https://www.ncbi.nlm.nih.gov/pubmed/21989185 http://dx.doi.org/10.1038/bjc.2011.377

Ejemplares similares

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation
por: Fallowfield, L J, et al.
Publicado: (2012)

Did We Get What We Aimed for 10 Years Ago?
por: Augustinus, A, et al.
Publicado: (2011)

The treatment of early breast cancer in women over the age of 70
por: Ring, A, et al.
Publicado: (2011)

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial
por: R, Leonard, et al.
Publicado: (2020)

Chest wall injury centers—how we did it
por: Forrester, Joseph D., et al.
Publicado: (2021)

Yes, we did it!
por: CERN Bulletin
Publicado: (2010)

Treatment of Gliomas: How did we get here?
por: Chowdhary, Michelle M., et al.
Publicado: (2015)

What else did we learn?
por: Pojer, M
Publicado: (2009)

Sorting the Magnets in the Machine: What did/will We Gain ?
por: Bottura, L
Publicado: (2006)

What did we know? what did we do?: making decisions in large organizations
por: Herzner, Fred, et al.
Publicado: (2018)

What did we learn in school today ?
por: Tröster, D A
Publicado: (1989)

Gene Drive for Mosquito Control: Where Did It Come from and Where Are We Headed?
por: Macias, Vanessa M., et al.
Publicado: (2017)

Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
por: Duric, V M, et al.
Publicado: (2005)

The Cause of Severe Acute Respiratory Syndrome: What Did We Learn from It?
por: Peiris, Malik, et al.
Publicado: (2020)

Muscle fatigue and muscle weakness: what we know and what we wish we did
por: Karatzaferi, Christina, et al.
Publicado: (2013)

Can we improve the professional and personal fulfillment of doctors in cancer medicine?
por: Fallowfield, L.
Publicado: (1995)

What did we learn today?
por: Midtvedt, Tore
Publicado: (2015)

Effects of COVID-19 pandemic on cardiac surgery and practice. Did we hit the mark: strategy or casuality?
por: Di Gaetano, M, et al.
Publicado: (2021)

Acute promyelocytic leukemia: where did we start, where are we now, and the future
por: Coombs, C C, et al.
Publicado: (2015)

Influenza vaccine supply, 2005–2006: did we come up short?
por: Bardenheier, Barbara H, et al.
Publicado: (2007)

Physiology labs during a pandemic: What did we learn?
por: Chen, Xinnian, et al.
Publicado: (2021)

What did we learn without beam in 2008: Summary of Session 1
por: Saban, R, et al.
Publicado: (2009)

LEP/SLC : What did we expect ? What did we achieve ? A very quick historical review
por: Treille, D
Publicado: (2001)

How and what did we do in 1999
por: Despas, C
Publicado: (2000)

Hereford and Cholera — Why Did We Escape It?
por: Ross, John
Publicado: (1990)

Sialyl-Tn in Cancer: (How) Did We Miss the Target?
por: Julien, Sylvain, et al.
Publicado: (2012)

Did We or Didn't We? Louse Genetic Analysis Says Yes
Publicado: (2004)

We can do much better than what we did
por: Lee, Sang-Hak
Publicado: (2020)

The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective
por: Kilburn, Lucy S, et al.
Publicado: (2014)

Viral Encephalitis in England, 1989–1998: What Did We Miss?
por: Davison, Katy L., et al.
Publicado: (2003)

Calcium and Heart Failure: How Did We Get Here and Where Are We Going?
por: Siri-Angkul, Natthaphat, et al.
Publicado: (2021)

The RF system to 102 GeV: how did we get there and can we go further?
por: Sladen, Jonathan P H
Publicado: (2000)

What did we learn with beam in 2008?: Summary of Session 7
por: Lamont, M
Publicado: (2009)

AI did not write this manuscript, or did it? Can we trick the AI text detector into generated texts? The potential future of ChatGPT and AI in Sports & Exercise Medicine manuscript generation
por: Anderson, Nash, et al.
Publicado: (2023)

What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?
por: Betensky, Marisol, et al.
Publicado: (2023)

Flowering plant embryos: How did we end up here?
por: Rensing, Stefan A., et al.
Publicado: (2021)

The national review of asthma deaths: what did we learn and what needs to change?
por: Levy, Mark L.
Publicado: (2015)

The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
por: Manders, P, et al.
Publicado: (2002)

Who coined the term “status gelasticus”? We did
por: Ng, Yu-tze
Publicado: (2009)

Smoking and COVID-19: Did we overlook representativeness?
por: Wenzl, Thomas
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_use16ib4mvcfmi2r7pde74r3hi